SCHEMBL8915100

SCHEMBL8915100

Cc1c[nH]c2c(O)cc3c(c12)[C@H](CCl)CN3C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ADH1A P07327 1/20 0.38
KIT P10721 1/20 0.38
FLT1 P17948 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
ABL2 P42684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8913783 1.00 ADH1A (0.38) ADH1AKITFLT1FLT4KDR
SCHEMBL6855095 0.88 ADH1A (0.37) ADH1AKITFLT1FLT4KDR
SCHEMBL16941957 0.87 ADH1A (0.30) ADH1AKITFLT1FLT4KDR
SCHEMBL9382078 0.85 ADH1A (0.42) ADH1AKITFLT1FLT4KDR
SCHEMBL9382386 0.85 ADH1A (0.42) ADH1AKITFLT1FLT4KDR
SCHEMBL9378522 0.85 ADH1A (0.42) ADH1AKITFLT1FLT4KDR
SCHEMBL7482550 0.82 TLR9 (0.34) ADH1AKITFLT1FLT4KDR
SCHEMBL16941959 0.82 TLR9 (0.34) ADH1AKITFLT1FLT4KDR
SCHEMBL8914778 0.82 ADH1A (0.42) ADH1AKITFLT1FLT4KDR
SCHEMBL20801853 0.82 ADH1A (0.43) ADH1AKITFLT1FLT4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3099692-B9 BIFUNCTIONAL CYTOTOXIC AGENTS PFIZER (US) 2019-11-13 EP disclosed
EP-3099692-B9 BIFUNCTIONAL CYTOTOXIC AGENTS PFIZER (US) 2019-11-13 EP disclosed
US-10391182-B2 Bifunctional cytotoxic agents PFIZER INC. (US) 2019-08-27 US disclosed
US-10391182-B2 Bifunctional cytotoxic agents PFIZER INC. (US) 2019-08-27 US disclosed
EP-3521292-A1 BIFUNCTIONAL CYTOTOXIC AGENTS Pfizer Inc (US) 2019-08-07 EP disclosed
EP-3521292-A1 BIFUNCTIONAL CYTOTOXIC AGENTS Pfizer Inc (US) 2019-08-07 EP disclosed
EP-3099692-B1 BIFUNCTIONAL CYTOTOXIC AGENTS PFIZER (US) 2019-03-13 EP disclosed
EP-3099692-B1 BIFUNCTIONAL CYTOTOXIC AGENTS PFIZER (US) 2019-03-13 EP disclosed
US-20180339060-A1 BIFUNCTIONAL CYTOTOXIC AGENTS PFIZER INC. (US) 2018-11-29 US disclosed
US-10086085-B2 Bifunctional cytotoxic agents PFIZER INC. (US) 2018-10-02 US disclosed
EP-3099692-A1 BIFUNCTIONAL CYTOTOXIC AGENTS Pfizer Inc. (US) 2016-12-07 EP disclosed
US-20150209445-A1 BIFUNCTIONAL CYTOTOXIC AGENTS PFIZER INC. 2015-07-30 US disclosed
US-20150209445-A1 BIFUNCTIONAL CYTOTOXIC AGENTS PFIZER INC. 2015-07-30 US disclosed
US-20150209445-A1 BIFUNCTIONAL CYTOTOXIC AGENTS PFIZER INC. 2015-07-30 US disclosed
WO-2015110935-A1 BIFUNCTIONAL CYTOTOXIC AGENTS PFIZER INC. (US) 2015-07-30 WO disclosed
WO-2015110935-A1 BIFUNCTIONAL CYTOTOXIC AGENTS PFIZER INC. (US) 2015-07-30 WO disclosed
US-5659022-A Oligonucleotide-cyclopropapyrroloindole conjugates as sequence specific hybridization and crosslinking agents for nucleic acids EPOCH PHARMACEUTICALS, INC. (US) 1997-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150209445-A1 BIFUNCTIONAL CYTOTOXIC AGENTS PAICS, CYTH3, CYTH2 ADH1A 3759/4885KIT 2300/4885FLT1 3066/4885
US-10086085-B2 Bifunctional cytotoxic agents PAICS, CYTH3, CYTH2 ADH1A 3759/4885KIT 2300/4885FLT1 3066/4885
US-10391182-B2 Bifunctional cytotoxic agents PAICS, CYTH3, CYTH2 ADH1A 3759/4885KIT 2300/4885FLT1 3066/4885
US-20180339060-A1 BIFUNCTIONAL CYTOTOXIC AGENTS PAICS, CYTH3, CYTH2 ADH1A 3759/4885KIT 2300/4885FLT1 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.